Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry J Goldstein

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Current Medical Research and Opinion|February 24, 2009
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week studyDebora Williams-Herman, Jeremy Johnson, Rujun Teng, et al.
Diabetes Care|August 28, 2015
Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 DiabetesWayne H-H Sheu, Ira Gantz, Menghui Chen, et al.
The Journal of Clinical Endocrinology and Metabolism|December 6, 2002
Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazoneHiroyuki Motoshima, Xiangdong Wu, Madhur K Sinha, et al.
American Journal of Physiology. Renal Physiology|September 15, 2005
Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cellsTaishan Hu, Satish P Ramachandrarao, Senthuran Siva, et al.
Plos One|August 28, 2015
Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention Program CohortKieren J Mather, Qing Pan, William C Knowler, et al.
Diabetes Care|December 19, 2012
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiencyJuan Camilo Arjona Ferreira, Michel Marre, Nir Barzilai, et al.
Diabetes Care|October 14, 2011
Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetesGary E Meininger, Russell Scott, Maria Alba, et al.
Journal of Diabetes|June 8, 2012
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetesWenying Yang, Yanfen Guan, Yue Shentu, et al.
Current Medical Research and Opinion|June 16, 2012
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) valueKarl J Krobot, Shannon Allen Ferrante, Michael J Davies, et al.
Diabetes Research and Clinical Practice|April 12, 2011
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizideThomas L Seck, Samuel S Engel, Debora E Williams-Herman, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Current Medical Research and Opinion|February 24, 2009
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week studyDebora Williams-Herman, Jeremy Johnson, Rujun Teng, et al.
Diabetes Care|August 28, 2015
Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 DiabetesWayne H-H Sheu, Ira Gantz, Menghui Chen, et al.
The Journal of Clinical Endocrinology and Metabolism|December 6, 2002
Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazoneHiroyuki Motoshima, Xiangdong Wu, Madhur K Sinha, et al.
American Journal of Physiology. Renal Physiology|September 15, 2005
Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cellsTaishan Hu, Satish P Ramachandrarao, Senthuran Siva, et al.
Plos One|August 28, 2015
Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention Program CohortKieren J Mather, Qing Pan, William C Knowler, et al.
Diabetes Care|December 19, 2012
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiencyJuan Camilo Arjona Ferreira, Michel Marre, Nir Barzilai, et al.
Diabetes Care|October 14, 2011
Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetesGary E Meininger, Russell Scott, Maria Alba, et al.
Journal of Diabetes|June 8, 2012
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetesWenying Yang, Yanfen Guan, Yue Shentu, et al.
Current Medical Research and Opinion|June 16, 2012
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) valueKarl J Krobot, Shannon Allen Ferrante, Michael J Davies, et al.
Diabetes Research and Clinical Practice|April 12, 2011
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizideThomas L Seck, Samuel S Engel, Debora E Williams-Herman, et al.
Pageof 8